CareDx, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 30, 2026, details two major strategic transactions completed by CareDx, Inc. (CDNA) on June 30 and July 1, 2026. The Company executed a divestiture of its European subsidiary and kitted laboratory products business while simultaneously acquiring Naveris, Inc.
Key Financial Metrics and Transaction Values
- Eurobio Transaction (Sale): The Company received an aggregate purchase price of $171.7 million in cash for the sale of CareDx AB and related assets to Eurobio Scientific S.A. This amount is subject to customary adjustments for working capital, cash, and indebtedness.
- Naveris Transaction (Acquisition): The Company paid an aggregate purchase price of $161.8 million in cash to acquire Naveris, Inc. This amount is subject to adjustments for cash, indebtedness, transaction expenses, and net working capital.
- Contingent Consideration: Naveris equityholders are eligible to receive up to an additional $100.0 million in cash contingent upon achieving specified revenue-based milestones for fiscal years ending December 31, 2026, and December 31, 2027.
- Net Cash Impact: Based on initial figures, the Company generated a net cash inflow of approximately $9.9 million from these two transactions, excluding working capital adjustments and transaction expenses.
Material Changes
The filing reports a significant restructuring of the Company's portfolio. The divestiture of the Swedish subsidiary and kitted laboratory products business marks an exit from that specific segment. Conversely, the acquisition of Naveris, Inc. represents a strategic expansion, with Naveris continuing as a wholly-owned subsidiary of CareDx.
Outlook, Risks, and Contingencies
- Future Obligations: The Company faces a potential future cash outflow of up to $100.0 million related to the Naveris acquisition, dependent on future revenue performance.
- Financial Reporting: Required financial statements for Naveris and pro forma financial information will be filed by amendment within 71 calendar days of this report.
- Adjustments: Final transaction values for both the sale and acquisition are subject to post-closing adjustments regarding working capital and cash balances.
Investor Verification Checklist
- Verify the final purchase price adjustments for both the Eurobio sale and Naveris acquisition once working capital and cash balances are finalized.
- Review the upcoming pro forma financial information (due within 71 days) to assess the combined entity's financial position.
- Monitor the revenue milestones for Naveris to determine the likelihood of the $100.0 million contingent payment.
- Confirm the integration strategy for Naveris and the operational impact of exiting the kitted laboratory products business.